Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$8.91 USD
-0.37 (-3.99%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $8.57 -0.34 (-3.82%) 7:20 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Balance Sheet
Fiscal Year End for Emergent Biosolutions Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 112 | 643 | 576 | 622 | 168 |
Receivables | 191 | 158 | 275 | 231 | 275 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 329 | 352 | 351 | 307 | 223 |
Other Current Assets | 48 | 58 | 70 | 37 | 20 |
Total Current Assets | 680 | 1,211 | 1,272 | 1,196 | 686 |
Net Property & Equipment | 383 | 818 | 800 | 644 | 542 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 13 |
Intangibles | 567 | 947 | 830 | 930 | 980 |
Deposits & Other Assets | 194 | 191 | 57 | 113 | 106 |
Total Assets | 1,823 | 3,167 | 2,959 | 2,883 | 2,327 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 112 | 104 | 129 | 136 | 95 |
Current Portion Long-Term Debt | 414 | 957 | 0 | 34 | 13 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 93 | 123 | 140 | 132 | 102 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 33 | 46 | 105 | 83 | 7 |
Total Current Liabilities | 651 | 1,230 | 374 | 385 | 216 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 47 | 72 | 95 | 109 | 150 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 447 | 449 | 809 | 841 | 798 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 29 | 33 | 62 | 102 | 75 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,174 | 1,784 | 1,340 | 1,436 | 1,239 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 904 | 874 | 829 | 785 | 716 |
Retained Earnings | -22 | 734 | 958 | 727 | 422 |
Other Equity | -6 | 3 | -16 | -25 | -10 |
Treasury Stock | 228 | 228 | 152 | 40 | 40 |
Total Shareholder's Equity | 649 | 1,383 | 1,619 | 1,447 | 1,089 |
Total Liabilities & Shareholder's Equity | 1,823 | 3,167 | 2,959 | 2,883 | 2,327 |
Total Common Equity | 649 | 1,383 | 1,619 | 1,447 | 1,089 |
Shares Outstanding | 51.80 | 49.80 | 53.80 | 53.00 | 51.60 |
Book Value Per Share | 12.53 | 27.77 | 30.09 | 27.30 | 21.09 |
Fiscal Year End for Emergent Biosolutions Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 71 | 79 | 112 | 88 | 89 |
Receivables | 196 | 234 | 191 | 217 | 290 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 318 | 333 | 329 | 354 | 354 |
Other Current Assets | 70 | 37 | 48 | 62 | 45 |
Total Current Assets | 655 | 682 | 680 | 721 | 778 |
Net Property & Equipment | 306 | 379 | 383 | 395 | 396 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 534 | 550 | 567 | 583 | 811 |
Deposits & Other Assets | 19 | 191 | 194 | 194 | 195 |
Total Assets | 1,514 | 1,804 | 1,823 | 1,893 | 2,179 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 96 | 100 | 112 | 113 | 108 |
Current Portion Long-Term Debt | 415 | 459 | 414 | 414 | 455 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 84 | 56 | 93 | 100 | 101 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 25 | 15 | 33 | 38 | 29 |
Total Current Liabilities | 620 | 630 | 651 | 664 | 693 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 35 | 35 | 47 | 52 | 58 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 447 | 447 | 447 | 448 | 448 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 26 | 29 | 31 | 23 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,127 | 1,140 | 1,174 | 1,196 | 1,223 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 915 | 910 | 904 | 900 | 896 |
Retained Earnings | -296 | -13 | -22 | 28 | 290 |
Other Equity | -6 | -6 | -6 | -3 | -2 |
Treasury Stock | 228 | 228 | 228 | 228 | 228 |
Total Shareholder's Equity | 386 | 664 | 649 | 697 | 956 |
Total Liabilities & Shareholder's Equity | 1,514 | 1,804 | 1,823 | 1,893 | 2,179 |
Total Common Equity | 386 | 664 | 649 | 697 | 956 |
Shares Outstanding | 52.90 | 52.40 | 51.80 | 51.80 | 50.40 |
Book Value Per Share | 7.30 | 12.67 | 12.53 | 13.46 | 18.97 |